EANS-News: AGENNIX AG /Agennix Awarded Approximately $490,000 Under U.S. Qualifying Therapeutic Discovery Project Grant Program

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Planegg/Munich (Germany), Princeton, NJ and Houston, TX (euro adhoc)
- November 5, 2010 - Agennix AG (Frankfurt Stock Exchange (Prime
Standard): AGX) today announced that its U.S. subsidiaries have
received approximately $490,000 in grants under the Qualifying
Therapeutic Discovery Project program, which is part of the U.S.
Patient Protection and Affordable Care Act. Two applications were
submitted under this program related to work with talactoferrin and
RGB-286638, the Company´s multi-targeted kinase inhibitor, and the
maximum grant was awarded to each project.

Torsten Hombeck, Ph.D., Chief Financial Officer, said: "We are
pleased to have been awarded these grants, which provide non-dilutive
funding for our development programs and which we believe are a
testament to the potential our work has to improve the length and
quality of patients´ lives in areas of unmet medical need."

About the Qualifying Therapeutic Discovery Project program The
Qualifying Therapeutic Discovery Project tax credit, which can also
be administered as a grant, is provided under section 48D of the U.S.
Internal Revenue Code (IRC), enacted as part of the Patient
Protection and Affordable Care Act of 2010. The program is targeted
to therapeutic discovery projects that show a reasonable potential to
result in new therapies to treat areas of unmet medical need or
prevent, detect or treat chronic or acute diseases and conditions; to
reduce the long-term growth of health care costs in the United
States; or to significantly advance the goal of curing cancer within
30 years. Allocation of the credit or grant also takes into
consideration which projects show the greatest potential to create
and sustain high-quality, high-paying U.S. jobs and to advance U.S.
competitiveness in life, biological and medical sciences. The credit
or grant is only available to taxpayers with no more than 250
employees.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company´s most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as
well as in severe sepsis. Talactoferrin is currently in Phase III
clinical trials in non-small cell lung cancer, and Agennix plans to
develop this program further for the treatment of severe sepsis.
Other clinical development programs include RGB-286638, a
multi-targeted kinase inhibitor in Phase I testing, and a topical gel
form of talactoferrin for diabetic foot ulcers. Agennix´s registered
seat is in Heidelberg, Germany. The Company has three sites of
operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix
Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the future.

Agennix™ is a trademark of the Agennix group.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Agennix AG

Investor Relations & Corporate Communications

Phone: +49 (0)89 8565 2693

ir@agennix.com

In the U.S.: Laurie Doyle

Director, Investor Relations & Corporate Communications

Phone: +1 609 524 5884

laurie.doyle@agennix.com

Additional media contact for Europe:

MC Services AG

Raimund Gabriel

Phone: +49 (0) 89 210 228 0

raimund.gabriel@mc-services.eu

Additional investor contact for Europe:

Trout International LLC

Lauren Williams, Vice President

Phone: +44 207 936 9325

lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade